GGrantIndex
← Leaderboards

S Kevin Li

University Of Cincinnati

$7,494,887
Attributed
$7,494,887
Total exposure
8
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $622.8K · FY200524
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$6,250,462 · 6
FDA$1,244,425 · 2

By mechanism

R01$4,930,826 · 3
U01$1,244,425 · 2
R21$838,597 · 2
R15$481,039 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Cincinnati

Same institution · by research overlap

Others in their field

Top investigators on “Drug Delivery Systems

Research focus

Drug Delivery SystemsPharmaceutical PreparationsIn VivoIn VitroToxic EffectAdverse EffectsTissuesMembraneRouteAffectTechnologyCellsAnimalsIontophoresisHealth Care CostsPropertyMonitorResistanceDoseDesignAge Related Macular DegenerationBaseAnimal ModelEye Diseases

Grant awards (29)

RNA Nanosystem for Posterior Eye Drug Delivery$400,574
R01 · FY2024 · EY · contact PI
RNA Nanosystem for Posterior Eye Drug Delivery$401,253
R01 · FY2023 · EY · contact PI
RNA Nanosystem for Posterior Eye Drug Delivery$395,744
R01 · FY2022 · EY · contact PI
RNA Nanosystem for Posterior Eye Drug Delivery$421,652
R01 · FY2021 · EY · contact PI
Characterization of gingival drug delivery to improve local treatment$481,039
R15 · FY2019 · DE · contact PI
RNA Nanoparticles for Ocular Drug Delivery to the Posterior Eye$193,302
R21 · FY2016 · EY · contact PI
Development of a Dissolution Method for Long-acting Periodontal Drug Products$125,000
U01 · FY2016 · FD · contact PI
Tiered Testing Strategy for Assessing Thermal Effects on Transdermal Products$250,000
U01 · FY2015 · FD · contact PI
RNA Nanoparticles for Ocular Drug Delivery to the Posterior Eye$247,753
R21 · FY2015 · EY · contact PI
Development of a Dissolution Method for Long-acting Periodontal Drug Products$125,000
U01 · FY2015 · FD · contact PI
Tiered Testing Strategy for Assessing Thermal Effects on Transdermal Products$249,995
U01 · FY2014 · FD · contact PI
Tiered Testing Strategy for Assessing Thermal Effects on Transdermal Products$494,430
U01 · FY2013 · FD · contact PI
Iontophoresis to Improve Nail Disease Treatment$230,814
R01 · FY2012 · GM · contact PI
Iontophoresis to Improve Nail Disease Treatment$230,814
R01 · FY2011 · GM · contact PI
Improved Method of Drug Delivery to the Inner Ear$188,616
R21 · FY2011 · DC · contact PI
Iontophoresis to Improve Nail Disease Treatment$233,145
R01 · FY2010 · GM · contact PI
Improved Method of Drug Delivery to the Inner Ear$208,926
R21 · FY2010 · DC · contact PI
Methods & Noninvasive PK Study to Improve Iontophoresis$73,337
R01 · FY2010 · EY · contact PI
Iontophoresis to Improve Nail Disease Treatment$235,500
R01 · FY2009 · GM · contact PI
Methods & Noninvasive PK Study to Improve Iontophoresis$292,144
R01 · FY2008 · EY · contact PI
Methods & Noninvasive PK Study to Improve Iontophoresis$298,106
R01 · FY2007 · EY · contact PI
Methods to Control Transdermal lontophoresis Variability$204,595
R01 · FY2007 · GM · contact PI
Methods & Noninvasive PK Study to Improve Iontophoresis$324,199
R01 · FY2006 · EY · contact PI
Methods to Control Transdermal lontophoresis Variability$210,706
R01 · FY2006 · GM · contact PI
Methods &Noninvasive PK Study to Improve Iontophoresis$280,000
R01 · FY2005 · EY
Methods to Control Transdermal lontophoresis Variability$210,154
R01 · FY2005 · GM
Methods &Noninvasive PK Study to Improve Iontophoresis$44,000
R01 · FY2005 · EY
Methods to Control Transdermal lontophoresis Variability$210,154
R01 · FY2004 · GM
Methods to Control Transdermal lontophoresis Variability$233,935
R01 · FY2003 · GM